Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00411-9/fulltext?dgcid=hubspot_email_conferencealerts_ecfs25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_AkCmZCoygZBzA4TFqTiNerdeMagxXxY2ekG5tkY6rIa6T51nA_sDgFbIEcrjyZqTjWuoY_iJGdSYKfSCSiuexEBDSHQ&_hsmi=363830654&utm_content=363830654&utm_source=hs_email